ZERO Biotech Delivers First Tb-161 PSMA Treatment in East Asia

Milestone Unlocked!

ZERO Biotech and RIT Biotech are proud to announce the successful administration of the first Terbium-161 (Tb-161) PSMA dose to a patient in Hong Kong.

To our knowledge, this represents the first Tb-161 PSMA treatment in East Asia—a major step forward for next-generation radioligand therapy in the region.

This milestone is more than a single patient treatment. It reflects months of paperwork, cross-border coordination, isotope logistics, clinical planning, quality control, and precise execution by a dedicated multidisciplinary team. Bringing an emerging radiopharmaceutical such as Tb-161 from planning to the clinic requires not only scientific vision, but also operational excellence.

Tb-161 is gaining global attention as a promising next-generation therapeutic radionuclide. Compared with Lutetium-177 (Lu-177), Tb-161 offers additional short-range electron emissions (conversion and Auger), which may provide enhanced therapeutic potential at the microscopic disease level. By introducing this technology into clinical practice in Hong Kong, ZERO Biotech is helping position Asia at the forefront of innovation in theranostics.

This first administration marks the beginning of a new chapter: expanding access to advanced PSMA-targeted radioligand therapy, accelerating regional clinical experience, and building the foundation for broader adoption of next-generation nuclear medicine across Asia.

This is Patient #1. 

Many more to come.

Stay tuned as we continue advancing the future of theranostics in Asia. 🧬🚀

Image credit: Kousik Ojha, Linkedin//